Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:17:46 2024-04-26 am EDT			5-day change	1st Jan Change
25.4 ^USD	+0.53%		-2.33%	-11.79%

03:43pm	Sector Update: Health Care Stocks Mixed Premarket Friday	MT
03:09pm	Pfizer Receives FDA Approval for Rare Bleeding Disorder Treatment	MT

PFIZER INC : Gets a Neutral rating from Barclays

November 03, 2021 at 12:26 pm EDT

In a research note, Barclays analyst Carter Gould has maintained his recommendation on the stock with a Neutral rating. The target price has been lifted and is now set at USD 44 compared to USD 41 before.

Latest news about Pfizer, Inc.

Sector Update: Health Care Stocks Mixed Premarket Friday	09:43am	MT
Pfizer Receives FDA Approval for Rare Bleeding Disorder Treatment	09:09am	MT
Pfizer Receives FDA Approval for Rare Bleeding Disorder Treatment	07:47am	MT
Pfizer Receives FDA Approval for Rare Bleeding Disorder Treatment	07:44am	MT
Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B	07:15am	DJ
US FDA approves Pfizer's gene therapy for rare bleeding disorder	06:46am	RE
Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	Apr. 25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	Apr. 25	MT
GSK Files Lawsuit Against Pfizer, BioNTech Over mRNA Patents Infringement	Apr. 25	MT
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology	Apr. 25	RE
Bristol Myers posts quarterly loss, revenue rises 5%	Apr. 25	RE
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Pfizer Keeps Q2 Dividend at $0.42 a Share, Payable June 14 to Holders of Record May 10	Apr. 24	MT
Pfizer Inc. Declares Second-Quarter 2024 Dividend, Payable on June 14, 2024	Apr. 24	CI
Edwards Lifesciences Corporation: The story continues	Apr. 23
Pfizer vs Moderna battle over COVID vaccine patents begins in UK	Apr. 23	RE
Pfizer: new Emblaveo antibiotic approved in the EU	Apr. 22	CF
Pfizer's Emblaveo Receives European Commission Marketing Approval	Apr. 22	MT
European Commission Approves Pfizer?s Emblaveo® for Patients with Multidrug-Resistant Infections and Limited Treatment Options	Apr. 22	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	Apr. 17	MT
Sector Update: Health Care	Apr. 17	MT
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	Apr. 17	MT
Tara Health Foundation Files an Exempt Solicitation Statement with Securities and Exchange Commission	Apr. 16	CI
News Highlights : Top Financial Services News of the Day - Monday at 11 AM ET	Apr. 15	DJ

Chart Pfizer, Inc.

Duration

Period

More charts

Company Profile

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am EST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 04:50 pm EDT

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.26 USD

Average target price

31.62 USD

Spread / Average Target

+25.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	-11.79%	143B
ELI LILLY AND COMPANY	+25.09%	653B
NOVO NORDISK A/S	+26.16%	556B
JOHNSON & JOHNSON	-6.26%	354B
MERCK & CO., INC.	+20.40%	331B
ABBVIE INC.	+3.83%	296B
ASTRAZENECA PLC	+12.58%	233B
NOVARTIS AG	+5.56%	201B
ROCHE HOLDING AG	-9.78%	193B
AMGEN INC.	-6.28%	144B

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

PFIZER INC : Gets a Neutral rating from Barclays

EPS Revisions